Trial Search Results

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

In this study, APX005M and Nivolumab will be taken in combination with 2 approved drugs called gemcitabine (“Gem”) and nab-paclitaxel (“NP”). Gem and NP are drugs that have already been approved by the FDA to treat participants with metastatic pancreatic adenocarcinoma. APX005M is an experimental protein molecule based on the structure of a naturally occurring human protein known as an immunoglobulin or antibody. It has been designed to stimulate your body’s immune system and to enhance its ability to fight the cancer in your body.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-6608
Not Recruiting